← Leaderboards
Richard K. Sterling
Virginia Commonwealth University
$9,383,090
Attributed
$10,302,318
Total exposure
30
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,302,318 · 30
By mechanism
U01$4,484,375 · 3
R01$3,497,000 · 1
M01$1,542,203 · 24
K23$632,685 · 1
R03$146,055 · 1
Top collaborators
- Andrea D. Branch3 shared
- Arun J Sanyal2 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Mary Jo E Grap$4,005,221
- Arun J Sanyal$37,042,537
- Velimer A Luketic$648
- Mitchell L Shiffman$2,507,516
- Velimir A Luketic$438,753
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelUnited States National Institutes Of HealthFundingHepatitis C VirusResourcesClinical ResearchNatural HistoryHistologicLiver DiseasesCohortLiverGrantSeveritiesInfectionHepatitis BBaseTenofovirChronic Hepatitis BResponseVirusPrimary Carcinoma Of The Liver CellsInstitutionHepatitis B VirusComputer Retrieval Of Information On Scientific Projects Database
Grant awards (56)
Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture$682,915
U01 · FY2025 · CA
Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture$325,920
U01 · FY2024 · CA
Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture$360,350
U01 · FY2023 · CA
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 9/9$116,733
U01 · FY2023 · AA · contact PI
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 9/9$352,539
U01 · FY2022 · AA · contact PI
Hepatitis B Clinical Research Network$226,146
U01 · FY2019 · DK · contact PI
Hepatitis B Clinical Research Network$276,570
U01 · FY2018 · DK · contact PI
HBV HIV Coinfection Research Network$525,000
R01 · FY2017 · DK · contact PI
HBV HIV Coinfection Research Network$372,000
R01 · FY2017 · DK · contact PI
Hepatitis B Clinical Research Network$306,857
U01 · FY2017 · DK · contact PI
HBV HIV Coinfection Research Network$525,000
R01 · FY2016 · DK · contact PI
Hepatitis B Clinical Research Network$218,817
U01 · FY2016 · DK · contact PI
HBV HIV Coinfection Research Network$525,000
R01 · FY2015 · DK · contact PI
Hepatitis B Clinical Research Network$238,843
U01 · FY2015 · DK · contact PI
HBV HIV Coinfection Research Network$525,000
R01 · FY2014 · DK · contact PI
HBV HIV Coinfection Research Network$500,000
R01 · FY2014 · DK · contact PI
Hepatitis B Clinical Research Network$253,302
U01 · FY2014 · DK · contact PI
HBV HIV Coinfection Research Network$525,000
R01 · FY2013 · DK · contact PI
Hepatitis B Clinical Research Network$320,318
U01 · FY2013 · DK · contact PI
Hepatitis B Clinical Research Network$245,033
U01 · FY2012 · DK · contact PI
Hepatitis B Clinical Research Network$223,662
U01 · FY2011 · DK · contact PI
Hepatitis B Clinical Research Network$336,370
U01 · FY2010 · DK · contact PI
HCV-HIV COINFECTION: IMPACT OF IMMUNE DYSFUNCTION$84,434
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: HEP C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C)$46,710
M01 · FY2010 · RR · contact PI
ANTIRETROVIRAL THERAPY AND THE HEPATITIS C VIRUS: A LIMITED CENTER TRIAL$23,656
M01 · FY2010 · RR · contact PI
RELATIONSHIP OF METABOLIC ABNORMALITIES TO HEPATIC STEATOSIS IN HUMAN$8,735
M01 · FY2010 · RR · contact PI
A PILOT STUDY OF THERAPY WITH PIOGLITAZONE PRIOR TO HCV TREATMENT IN HIV-1 AN$2,912
M01 · FY2010 · RR · contact PI
THE RELATIONSHIP OF HEPATIC STEATOSIS TO ENDOTHELIAL DYSFUNCTION IN PATIENTS$2,912
M01 · FY2010 · RR · contact PI
SPECTRUM OF LIVER DISEASE IN PATIENTS LIVING WITH HIV$2,184
M01 · FY2010 · RR · contact PI
HCV-HIV COINFECTION: IMPACT OF IMMUNE DYSFUNCTION$250,861
M01 · FY2009 · RR · contact PI
RELATIONSHIP OF METABOLIC ABNORMALITIES TO HEPATIC STEATOSIS IN HUMAN IMMUNOD$22,371
M01 · FY2009 · RR · contact PI
HCV-HIV COINFECTION: IMPACT OF IMMUNE DYSFUNCTION$354,208
M01 · FY2008 · RR · contact PI
Relationship of metabolic abnormalities to hepatic steatosis in HIV$72,290
R03 · FY2008 · DK · contact PI
RELATIONSHIP OF METABOLIC ABNORMALITIES TO HEPATIC STEATOSIS IN HUMAN IMMUNOD$12,508
M01 · FY2008 · RR · contact PI
HCV-HIV COINFECTION: IMPACT OF IMMUNE DYSFUNCTION$175,962
M01 · FY2007 · RR · contact PI
HCV-HIV Coinfection: Impact of Immune Dysfunction$126,568
K23 · FY2007 · DK · contact PI
Relationship of metabolic abnormalities to hepatic steatosis in HIV$73,765
R03 · FY2007 · DK · contact PI
PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN IN CHRONIC HEPATITIS C AND HIV$4,551
M01 · FY2007 · RR · contact PI
HCV-HIV Coinfection: Impact of Immune Dysfunction$125,934
K23 · FY2006 · DK · contact PI
HCV-HIV COINFECTION: IMPACT OF IMMUNE DYSFUNCTION$88,219
M01 · FY2006 · RR · contact PI
PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN IN CHRONIC HEPATITIS C AND HIV$33,608
M01 · FY2006 · RR · contact PI
THE IMMUNOLOGIC EFFECTS OF (HCV)IN PATIENTS WITH HIV COINFECTION$7,351
M01 · FY2006 · RR · contact PI
PEG_INTERFERON A-2B + RIBIVIRIN FOR TREATMENT OF HCV IN HIV INFECTED PERSONS$5,252
M01 · FY2006 · RR · contact PI
HCV-HIV Coinfection: Impact of Immune Dysfunction$126,405
K23 · FY2005 · DK
PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN IN CHRONIC HEPATITIS C AND HIV$94,680
M01 · FY2005 · RR
PEG_INTERFERON A-2B + RIBIVIRIN FOR TREATMENT OF HCV IN HIV INFECTED PERSONS$87,317
M01 · FY2005 · RR
THE IMMUNOLOGIC EFFECTS OF (HCV)IN PATIENTS WITH HIV COINFECTION$73,639
M01 · FY2005 · RR
HCV-HIV COINFECTION: IMPACT OF IMMUNE DYSFUNCTION$13,675
M01 · FY2005 · RR
THE SPECTRUM AND IMMUNOLOGIC EFFECTS OF HCV IN PATIENTS WITH HIV$2,106
M01 · FY2005 · RR
HCV-HIV Coinfection: Impact of Immune Dysfunction$124,331
K23 · FY2004 · DK
Immunologic effects of HCV in patients with HIV coinfect$72,743
M01 · FY2004 · RR
PEG-INTERFERON A-2B + RIBAVIRIN FOR TREATMENT OF HCV$69,176
M01 · FY2004 · RR
Immunologic effects of HCV in patients with HIV$1,427
M01 · FY2004 · RR
Mycophenolate Mofetil in Primary Sclerosing Cholangitis$1,006
M01 · FY2004 · RR
HCV-HIV Coinfection: Impact of Immune Dysfunction$129,447
K23 · FY2003 · DK
GLUCOSE METABOLISM IN HEPATITIS C--GLUCOSE INTOLERANCE$0
M01 · FY2000 · RR